An observational study in Cardiovascular Diseases and Vesicle, sponsored by G. d'Annunzio University. Completed. Per ClinicalTrials.gov, last updated 2022-10-18.
Sponsored by G. d'Annunzio University · Observational
Extracellular vesicles (EVs) are small vesicles deriving from all cell types during cell activation, involved in transcellular communication, and regarded as predictors of vascular damage and of cardiovascular events. The investigators will test the hypothesis that, in patients on chronic low-dose aspirin treatment for cardiovascular prevention, aspirin may affect the release of EVs within the 24 hours interval.
5,025 studies on the registry are indexed under Cardiovascular Diseases; 928 are open to participants now.
This study's enrollment of 93 is below the median of 600 across 1,524 observational studies indexed under Cardiovascular Diseases.
Browse Cardiovascular Diseases studies →G. d'Annunzio University is the lead sponsor of 65 studies on the registry; 21 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients on low-dose aspirin treatment for cardiovascular prevention (enteric coated, Cardio aspirin 100 mg/die Bayer, Milan, Italy) once daily (o.d.) for at least 1 month
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
A total of 84 patients on chronic treatment with low-dose ASA (enteric coated, Cardio aspirin 100 mg/die Bayer, Milan, Italy) once daily (o.d.) for at least 1 month
9 healthy subjects, not on ASA treatment, as controls.
Kinetics of circulating extracellular vesicles after low-dose aspirin administration
In patients receiving low-dose aspirin for cardiovascular prevention, evaluate the potential effects of chronic aspirin treatment on circulating extracellular vesicles levels over the 24-hour interval
Time frame: 1st - 12th month
Aspirin response and circulating extracellular vesicles over the 24-hour
In patients receiving low-dose aspirin for cardiovascular prevention, evaluate the role of circulating extracellular vesicles as a potential determinant of interindividual variability in the aspirin response
Time frame: 13th - 24th month
No study locations are listed for this record.
The record gives a start of Sep 2015, a primary completion of May 2017 and a completion of Dec 2017. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
G. d'Annunzio University